Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 10/20 | 0.66 |
| ▸ | NPC1 | O15118 | 10/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | CASP3 | P42574 | 1/20 | 0.59 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2813859 | 1.00 | RAB9A (0.66) | RAB9ANPC1SMN1; SMN2LMNAMAPT | |
| SCHEMBL28466842 | 0.93 | MAPT (0.57) | RAB9ANPC1SMN1; SMN2LMNAMAPT | |
| SCHEMBL13937031 | 0.86 | RAB9A (0.65) | RAB9ANPC1SMN1; SMN2LMNAMAPT | |
| SCHEMBL28322545 | 0.85 | HPGD (0.60) | RAB9ANPC1SMN1; SMN2LMNAMAPT | |
| SCHEMBL28876868 | 0.85 | HPGD (0.60) | RAB9ANPC1SMN1; SMN2LMNAMAPT | |
| SCHEMBL29440964 | 0.85 | HPGD (0.60) | RAB9ANPC1SMN1; SMN2LMNAMAPT | |
| SCHEMBL417903 | 0.85 | RAB9A (0.67) | RAB9ANPC1SMN1; SMN2LMNAMAPT | |
| SCHEMBL565748 | 0.85 | RAB9A (0.67) | RAB9ANPC1SMN1; SMN2LMNAMAPT | |
| SCHEMBL417902 | 0.85 | RAB9A (0.67) | RAB9ANPC1SMN1; SMN2LMNAMAPT | |
| SCHEMBL2614739 | 0.84 | MAPT (0.60) | RAB9ANPC1SMN1; SMN2LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2188273-B1 | SUBSTITUTED TETRA HYDRO NAPHTHALINES, METHOD FOR THEIR MANUFACTURE AND THEIR USE AS DRUGS | SANOFI SA (FR) | 2014-10-22 | — | — | EP | disclosed |
| US-20140088077-A1 | NOVEL SUBSTITUTED TETRAHYDRONAPHTHALENES, PROCESS FOR THE PREPARATION THEREOF AND THE USE THEREOF AS MEDICAMENTS | SANOFI (FR) | 2014-03-27 | — | — | US | disclosed |
| US-8609731-B2 | Substituted tetrahydronaphthalenes, process for the preparation thereof and the use thereof as medicaments | SANOFI (FR) | 2013-12-17 | — | — | US | disclosed |
| US-20100249097-A1 | NOVEL SUBSTITUTED TETRAHYDRONAPHTHALENES, PROCESS FOR THE PREPARATION THEREOF AND THE USE THEREOF AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2010-09-30 | — | — | US | disclosed |
| EP-2188273-A2 | NOVEL SUBSTITUTED TETRAHYDRONAPHTHALENES, PROCESS FOR THE PREPARATION THEREOF AND THE USE THEREOF AS MEDICAMENTS | Sanofi-Aventis (FR) | 2010-05-26 | — | — | EP | disclosed |
| WO-2009021740-A2 | SUBSTITUTED TETRAHYDRONAPHTHALENES, PROCESS FOR THE PREPARATION THEREOF AND THE USE THEREOF AS MEDICAMENTS | SANOFIS-AVENTIS (FR) | 2009-02-19 | — | — | WO | disclosed |
| EP-2025674-A1 | Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs | sanofi-aventis (FR) | 2009-02-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140088077-A1 | NOVEL SUBSTITUTED TETRAHYDRONAPHTHALENES, PROCESS FOR THE PREPARATION THEREOF AND THE USE THEREOF AS MEDICAMENTS | DHPS, CYP11B2, CYP11B1 | RAB9A 3214/4885NPC1 403/4885SMN1; SMN2 3949/4885 |
| US-20100249097-A1 | NOVEL SUBSTITUTED TETRAHYDRONAPHTHALENES, PROCESS FOR THE PREPARATION THEREOF AND THE USE THEREOF AS MEDICAMENTS | DHPS, CYP11B2, CYP11B1 | RAB9A 3214/4885NPC1 403/4885SMN1; SMN2 3949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.